Ad-hoc | 9 August 2005 20:48

STRATEC AG: STRATEC and DiaSorin expand OEM partnership

Ad hoc announcement §15 WpHG Conclusion of a contract STRATEC AG: STRATEC and DiaSorin expand OEM partnership Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— STRATEC and DiaSorin expand OEM partnership Birkenfeld, August 9, 2005 On August 9, 2005, STRATEC Biomedical Systems AG, Birkenfeld, Germany, and DiaSorin S.p.A., Saluggia, Italy, concluded agreements covering the expansion of the existing OEM partnership in the field of the well established “LIAISON technology” (luminescence immunoassay technology). The agreements include the development and manufacture of a next-generation analyzer system. The completion of the development intended for 2007/2008 will be followed by the supply of a guaranteed number of analyzer systems over a period of several years. Additionally, the agreements include the prolongation of the existing contract for the “LIAISON” analyzer system, currently the product generating the highest sales for STRATEC Biomedical Systems AG. DiaSorin is committed to market the next-generation systems to gain access to new markets and to enhance and modernise existing system placements. For competitive reasons the companies agreed to maintain silence regarding the essentials of the agreement. STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland ISIN: DE0007289001 WKN: 728900 Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart (Gate-M); Freiverkehr in Berlin-Bremen, Düsseldorf und München End of ad hoc announcement (c)DGAP 09.08.2005 Issuer’s information/explanatory remarks concerning this ad hoc announcement: About the LIAISON analyzer system Being an integral part of the “LIAISON technology”, the well known “LIAISON” analyzer system has been developed by STRATEC for its then OEM customer Byk Sangtec Diagnostica GmbH & Co. KG that has become part of the DiaSorin Diagnostic Group in January 2003. With a total of more than 550 systems placed by DiaSorin in 2003 and 2004, over 1,500 systems have been installed around the world since its launch in 1997. As a combination of test reagents and analyzer system the “LIAISON technology” is used in a multitude of fully automated diagnostic applications such as serology testing for infectious diseases (e.g. hepatitis), hormone testing (e.g. thyroid hormone) and oncology (e.g. testing for tumor markers). About DiaSorin DiaSorin, headquartered in Salluggia, Italy, develops and manufactures reagents for in vitro diagnostics. Two additional production sites are located in Stillwater, Minnesota USA, and in Dietzenbach, Germany. With a large catalog of high quality products in the fields of infectious disease, hepatitis, endocrinology, bone and mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity, DiaSorin is dedicated to improving the quality of life by way of assays that allow improved diagnostic decision. DiaSorin’s objective is to strengthen its presence in the global diagnostics market by focusing and responding to the changing customers and market needs. DiaSorin sells its products worldwide directly through 11 subsidiaries and branch offices and as well as through an international network of over 80 distributors. About STRATEC Biomedical Systems AG STRATEC ( http://www.stratec-biomedical.de ) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the trading segment Gate- M of the Stuttgart Stock Exchange and on other exchanges. The STRATEC group comprises the listed holding company “STRATEC Biomedical Systems AG” as well as the wholly owned subsidiaries “STRATEC NewGen GmbH” and “Robion AG”. Conference call / publication of interim report rescheduled In connection with the publication of the interim report as of June 30, 2005 and in view of this ad hoc announcement, Marcus Wolfinger, CFO of STRATEC Biomedical Systems AG, will be available to provide further information in a conference call to be held at 10.30 a.m. on Wednesday, August 10, 2005. For the reasons outlined, the publication of the interim report has been brought forward by seven hours. The report can be downloaded from our website on Wednesday, August 10, 2005 as of 8.00 a.m. Further information can be obtained from: STRATEC Biomedical Systems AG Investor Relations André Loy Gewerbestrasse 37 75217 Birkenfeld Germany Tel: +49 (0)7082 7916-190 Fax: +49 (0)7082 7916-999 E-Mail: ir@stratec-biomedical.de End of message (c)DGAP 092048 Aug 05